Welcome to our dedicated page for Incannex Healthcare news (Ticker: IXHL), a resource for investors and traders seeking the latest updates and insights on Incannex Healthcare stock.
Incannex Healthcare Inc. reports company developments tied to its clinical-stage combination therapy pipeline, Nasdaq listing status and capital actions. Recurring updates describe IHL-42X, its oral fixed-dose combination program for obstructive sleep apnea, including clinical development strategy, sleep-medicine research partnerships and FDA Fast Track Designation.
News also covers PSX-001, the company’s oral synthetic botanical research compound formulation for generalized anxiety disorder, along with balance-sheet commentary, share repurchase activity, reverse stock split disclosures and Nasdaq minimum bid price compliance. The company’s communications generally center on clinical progress, regulatory context, financing capacity and public-company capital structure.
Incannex Healthcare (Nasdaq: IXHL) has reactivated its previously approved share repurchase program and executed repurchases over the past two trading days. The Board cited a belief that market valuation understates the company’s balance sheet, clinical progress, and future potential.
The company reported approximately $75 million in cash and no debt after recent financing, and stated that about $18.5 million remained available for repurchases as of December 31, 2025. The program is discretionary and may be modified, suspended, or discontinued.
Incannex Healthcare (Nasdaq: IXHL) has partnered with the AASM Foundation to sponsor a 2026 Focused Projects Grant for junior investigators in sleep apnea research and joined the Foundation’s Corporate Recognition Program.
Incannex continues advancing IHL-42X — an oral dronabinol/acetazolamide combination — after positive Phase 2 results, FDA Fast Track designation, and initiation of the DReAMzz Phase 2 dose-optimisation study with patient dosing expected within months toward a planned Phase 3 pathway.
Incannex (Nasdaq: IXHL) reported approximately $75 million in cash and no debt after a recent financing, while market capitalization is about $46 million, producing a negative enterprise value. Proceeds will fund the DReAMzz Phase 2 dose-optimization study for IHL-42X; PSX-001 development continues with an open IND.
The company expects to begin dosing in DReAMzz in the coming months and retains a board-approved share buyback program.
Incannex Healthcare (Nasdaq: IXHL) regained compliance with Nasdaq Listing Rule 5550(a)(2) after its common stock maintained a closing bid of $1.00 or greater for eleven consecutive business days from February 27 through March 13, 2026. Nasdaq has confirmed the company satisfied continued listing requirements and the matter is closed.
The company reported approximately $75 million in cash, no debt, and cited ongoing clinical development of IHL-42X for obstructive sleep apnea (statistically significant Phase 2) and PSX-001 for generalized anxiety disorder (positive outcomes).
Incannex Healthcare (Nasdaq: IXHL) priced a registered direct offering to raise approximately $10.0 million by issuing 2,000,000 common shares and accompanying warrants at a combined purchase price of $5.00 per share, expected to close on or about March 13, 2026.
If all warrants are exercised for cash at an exercise price of $6.50, Incannex could receive up to an additional $13.0 million, bringing total potential gross proceeds to about $23.0 million. Proceeds are expected to fund completion of the DReAMzz Phase 2 study for IHL-42X and for working capital; the company has terminated its ATM facility.
Incannex (Nasdaq: IXHL) announced an enhanced development pathway for oral OSA candidate IHL-42X after statistically significant Phase 2 RePOSA results and receipt of FDA Fast Track designation. The company will run a Phase 2 crossover dose-optimization study (DReAMzz) testing dronabinol/acetazolamide ratios, then pursue a streamlined Phase 3 master-protocol program to strengthen efficacy data and improve capital efficiency. Incannex expects to begin dosing in DReAMzz in the coming months.
Incannex (Nasdaq: IXHL) approved a 1-for-30 reverse stock split to be effective 4:01 p.m. ET on February 26, 2026 and will trade on a split-adjusted basis on February 27, 2026.
The reverse split will convert each 30 pre-split shares into one post-split share, reducing outstanding shares from approximately 358,329,368 to about 11,944,313. No fractional-share cash payments will be made; fractional interests will be rounded up. Proportional adjustments will apply to equity awards and the stock incentive plan.
Incannex Healthcare (Nasdaq: IXHL) announced three additions to its Clinical Advisory Board on January 29, 2026: Murray B. Stein, MD, MPH; Andrew Cutler, MD; and Amir Kalali, MD. The CAB will provide independent clinical and scientific guidance as PSX-001 advances, advising on trial design, endpoint selection, regulatory engagement, and development strategy.
The appointments broaden expertise in psychiatry, neurobiology, psychopharmacology, and clinical development to support disciplined execution and inform key clinical and regulatory decisions for the program.
Incannex Healthcare (Nasdaq: IXHL) announced on January 22, 2026 the formation of a Clinical Advisory Board to support the PSX-001 program in generalized anxiety disorder. The CAB will provide independent clinical, scientific, and regulatory guidance as PSX-001 advances to its next phase, advising on trial design, endpoint selection, and regulatory engagement. The inaugural members include C. Neill Epperson, Charles B. Nemeroff, and Alan F. Schatzberg, all senior psychiatry researchers with extensive publication and NIH-funded research histories.
Incannex Healthcare (Nasdaq: IXHL) was awarded the Research and Development Award in the Respiratory Disorders category at the 2025 Clinical Trials Arena Excellence Awards for its work on IHL-42X, an oral fixed-dose combination for moderate-to-severe obstructive sleep apnea (OSA).
The program is described as late-stage and supported by a Phase 2 clinical program with objective polysomnography outcomes, validated patient-reported measures, and structured exit interviews; the release states a favorable safety and tolerability profile observed to date and continued development toward potential chronic use if approved.